Máj- és epeúti rák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PD-1 92
• PD-L1 51
• TP53 3
• PI3K 0
• mTOR 1
• AKT 0
• STAT3 1
• VEGF 20
• FGFR 22
• GPC3 38
• CTNNB1 5
• YAP 0
• HER2 28
• MAPK 0
• NRF2 0
• HIF-1 0
• PPAR 0
• ERK 0
• AMPK 0
• EGFR 8
• STING 0
• CTLA-4 20
• MYC 0
• IDH 6
• JAK 0
• JNK 0
• PTEN 0
• GPX4 0
• KRAS 8
• BCL-2 0
• HSP90 0
• IL-6 1
• PSMA 8
• MET 1
• GLP-1 1
• BRAF 3
• EZH2 0
• NLRP3 0
• CLDN18 10
• MEK 0
• B7-H3 5
• COX-2 0
• HDAC 0
• CXCR4 0
• HMGB1 0
• METTL3 0
• SIRT1 0
• TLR4 0
• MMP-9 0
• TNF 0
• PARP 2
• PCSK9 0
• TIGIT 2
• TIM-3 1
• CDK4/6 0
• IL-17 0
• RAS 2
• SGLT2 0
• CD47 0
• IL-15 2

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · U19

  Rational hepatitis C virus vaccine design informed by mechanisms of spontaneous clearance or persistence of infection

  Johns Hopkins University· Baltimore, Egyesült Államok· 2 849 722 USD awarded in fiscal year 2026· until 2031. júl.

• NIH NCI · R44

  Overcoming Immune Evasion in Hepatocellular Carcinoma with Engineered T-Cell Therapy

  March Biosciences Inc· Houston, Egyesült Államok· 399 003 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NIDDK · R01

  Stakeholder Engagement and Modeling for Adoption of a Novel Cirrhosis Detection Algorithm

  University of Michigan at Ann Arbor· Ann Arbor, Egyesült Államok· 810 994 USD awarded in fiscal year 2026· until 2030. jún.

• NIH NIAAA · R16

  Phytol and alcohol-associated liver disease

  Marshall University· Huntington, Egyesült Államok· 146 549 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · R01

  Assessment of sound waves from liver vessels via artificial intelligence to detect liver cancer

  University of Minnesota· Minneapolis, Egyesült Államok· 18 735 USD awarded in fiscal year 2026· until 2031. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glutaminase Isoenzymes: Gatekeepers of Bioenergetics, Immunity, and Tumor Microenvironment in Diabetes-Induced Hepatocellular Carcinoma (IRM)

  Fundacion Para la Investigacion de Malaga En Biomedicina y Salud· Malaga, Spanyolország· EU contribution 209 915 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding Neural Circuits in Cholangiocarcinoma (LIVER-CIRCUITS)

  Technische Universitaet Dresden· Dresden, Németország· EU contribution 1 500 000 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling Malignant Cholangiocyte Subpopulations that Drive Chemoresistance in Cholangiocarcinoma (RESIST-CCA)

  Humanitas Mirasole Spa· Rozzano (Mi), Olaszország· EU contribution 193 643 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Multiscale 3D virtual histology with non-destructive x-rays (XHIST)

  Danmarks Tekniske Universitet· Kongens Lyngby, Dánia· EU contribution 150 000 EUR· until 2028. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Mechano-metabOlic Responsive nanoPlatform for HeterogEnous tUmor Suppression (MORPHEUS)

  Fundacion de la Comunidad Valenciana Centro de Investigacion Principe Felipe· Valencia, Spanyolország· EU contribution 2 499 745 EUR· until 2031. aug.

  The disease is named only in the funder's project summary, not in the title.

10 of 888 running projects, newest first. Listed amounts together: 485,7 M USD + 133,0 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

  NCT05564403· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 109
• Organoids 40
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 34
• Gene Expression Profiling 281
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 9
• Exome Sequencing 19
• Proteomics 119
• Metabolomics 73
• Mass Spectrometry 23
• Flow Cytometry 66
• Immunohistochemistry 125
• Liquid Biopsy 34
• Circulating Tumor DNA 42
• Xenograft Model Antitumor Assays 443
• Positron-Emission Tomography 35
• Magnetic Resonance Imaging 376
• Machine Learning 199
• Deep Learning 114
• Cohort Studies 184
• Genome-Wide Association Study 42

• A Pseudo-Targeted Method for Global Profiling of Cholesteryl Esters by Liquid Chromatography-Zeno High-Resolution Multiple Reaction Monitoring Mass Spectrometry.

  Anal Chem, 2026. nov.

• Phytochemical Profiling and Anticancer Potential of Ipomoea hederifolia L. Root Extract: LC-MS Characterization and Molecular Docking Insights.

  Chem Biodivers, 2026. nov.

• Serial Analyses with Mass Spectrometry Imaging Reveal Chemical and Metabolic Alterations in Liver Tissue Following Thermoembolization.

  J Am Soc Mass Spectrom, 2026. okt.

• CD147-SNAP-tag-CMC/HPLC-MS two-dimensional coupling system: a universal platform for screening active components targeting CD147 for anti-liver cancer applications.

  J Chromatogr B Analyt Technol Biomed Life Sci, 2026. szept.

• Secondary Amine-Based Chemical Isotope Labeling Coupled with Mass Spectrometry for Simultaneous Quantification of Carboxylic Compounds during Hepatocellular Carcinoma Progression.

  Anal Chem, 2026. aug.

• Integrated LiP-MS and quantitative proteomics reveal coordinated alterations in protein conformation and expression across tumor and peritumoral regions in hepatocellular carcinoma.

  Sci Rep, 2026. júl.

• Integrating UHPLC-Q-TOF-MS, Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulations to Reveal the Potential Mechanisms of Yiguanjian Decoction in Treating Liver Cancer.

  Chem Biodivers, 2026. máj.

• Spatially-guided metabolomics profiling of metabolic regions in human tumor tissues.

  Mol Syst Biol, 2026. ápr.

• Univariate- and machine learning-based plasma metabolite signature differentiates PSC-IBD from IBD and is predicted to be driven by gut microbial changes.

  Metabolomics, 2026. márc.

• Systemic serum protein alterations and molecular mechanisms in alcohol dependence.

  PeerJ, 2026. febr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.